Bioarctic was behind the early development of Leqembi (lecanemab), the first approved drug proven to slow the progression of Alzheimer's disease, but the company is also running several projects within other neurodegenerative diseases. One of these is exidavnemab, which is being developed as a new disease-modifying treatment for multiple system atr...